Advertisement

Pediatric Cardiology

, Volume 33, Issue 3, pp 394–401 | Cite as

Attention-Deficit/Hyperactivity Disorder, Stimulant Therapy, and the Patient with Congenital Heart Disease: Evidence and Reason

  • Anjan S. BatraEmail author
  • Mark E. Alexander
  • Michael J. Silka
Review Article

Abstract

Attention-deficit/hyperactivity disorder (ADHD) is the most common neurobehavioral disorder of childhood, and congenital heart disease (CHD) is the most common form of birth defect. Children with CHD are at increased risk for neurodevelopmental disorders such as ADHD. Stimulant medications, specifically methylphenidates and amphetamines, are frequently prescribed and effective in reducing the symptoms of ADHD. Despite their efficacy and long history of use, the safety of these medications has recently come into question due to isolated reports describing sudden unexplained death of children undergoing treatment. This review summarizes the current literature on the cardiovascular risks associated with the use of pharmacologic therapy for ADHD, with an emphasis on patients who had CHD.

Keywords

Attention-deficit/hyperactivity disorder Congenital heart disease Stimulant medications Sudden death 

References

  1. 1.
    Alexander M et al (2011) PACES survey. Presented at the HRS annual meetingGoogle Scholar
  2. 2.
    American Academy of Pediatrics, Steering Committee on Quality Improvement and Management (2004) Classifying recommendations for clinical practice guidelines. Pediatrics 114:874–877Google Scholar
  3. 3.
    Barbaresi WJ, Katusic SK, Colligan RC, Pankratz VS, Weaver AL, Weber KJ, Mrazek DA, Jacobsen SJ (2002) How common is attention-deficit/hyperactivity disorder? Incidence in a population-based birth cohort in Rochester, Minnesota. Arch Pediatr Adolesc Med 156:217–224PubMedGoogle Scholar
  4. 4.
    Berger S, Campbell R, Drezner J (2009) PACES survey. http://www.pediatricepsociety.org/links/. Accessed Sep 2011
  5. 5.
    Biederman J, Lopez FA, Boellner SW, Chandler MC (2002) A randomized, double-blind, placebo-controlled, parallel-group study of SLI381 (Adderall XR) in children with attention-deficit/hyperactivity disorder. Pediatrics 110:258–266PubMedCrossRefGoogle Scholar
  6. 6.
    Brown RT, Freeman WS, Perrin JM, Stein MT, Amler RW, Feldman HM, Pierce K, Wolraich ML (2001) Prevalence and assessment of attention-deficit/hyperactivity disorder in primary care settings. Pediatrics 107:E43PubMedCrossRefGoogle Scholar
  7. 7.
    Conway J, Wong KK, O’Connell C, Warren AE (2008) Cardiovascular risk screening before starting stimulant medications and prescribing practices of Canadian physicians: impact of the Health Canada Advisory. Pediatrics 122:e828–e834PubMedCrossRefGoogle Scholar
  8. 8.
    Findling RL, Short EJ, Manos MJ (2001) Short-term cardiovascular effects of methylphenidate and Adderall. J Am Acad Child Adolesc Psychiatry 40:525–529PubMedCrossRefGoogle Scholar
  9. 9.
    Findling RL, Biederman J, Wilens TE, Spencer TJ, McGough JJ, Lopez FA, Tulloch SJ (2005) Short- and long-term cardiovascular effects of mixed amphetamine salts extended release in children. J Pediatr 147:348–354PubMedCrossRefGoogle Scholar
  10. 10.
    Gothelf D, Gruber R, Presburger G, Dotan I, Brand-Gothelf A, Burg M, Inbar D, Steinberg T, Frisch A, Apter A, Weizman A (2003) Methylphenidate treatment for attention-deficit/hyperactivity disorder in children and adolescents with velocardiofacial syndrome: an open-label study. J Clin Psychiatry 64:1163–1169PubMedCrossRefGoogle Scholar
  11. 11.
    Gould MS, Walsh BT, Munfakh JL, Kleinman M, Duan N, Olfson M, Greenhill L, Cooper T (2009) Sudden death and use of stimulant medications in youths. Am J Psychiatry 166:992–1001PubMedCrossRefGoogle Scholar
  12. 12.
    Gutgesell H, Atkins D, Barst R, Buck M, Franklin W, Humes R, Ringel R, Shaddy R, Taubert KA (1999) AHA scientific statement: cardiovascular monitoring of children and adolescents receiving psychotropic drugs. Circulation 99:979–982PubMedGoogle Scholar
  13. 13.
  14. 14.
    Hoffman JI, Kaplan S, Liberthson RR (2004) Prevalence of congenital heart disease. Am Heart J 147:425–439PubMedCrossRefGoogle Scholar
  15. 15.
    Kirshbom PM, Flynn TB, Clancy RR, Ittenbach RF, Hartman DM, Paridon SM, Wernovsky G, Spray TL, Gaynor JW (2005) Late neurodevelopmental outcomes after repair of total anomalous pulmonary venous connections. J Thorac Cardiovasc Surg 129:1091–1096PubMedCrossRefGoogle Scholar
  16. 16.
    Mahle WT, Clancy RR, Moss EM, Gerdes M, Jobes DR, Wernovsky G (2000) Neurodevelopmental outcome and lifestyle assessment in school-aged and adolescent children with hypoplastic left heart syndrome. Pediatrics 105:1082–1089PubMedCrossRefGoogle Scholar
  17. 17.
    McCarthy S, Cranswick N, Potts L, Taylor E, Wong IC (2009) Mortality associated with attention-deficit hyperactivity disorder (ADHD) drug treatment: a retrospective cohort study of children, adolescents, and young adults using the general practice research database. Drug Saf 32:1089–1096PubMedCrossRefGoogle Scholar
  18. 18.
    Perrin JM, Friedman RA, Knilans TK (2008) Cardiovascular monitoring and stimulant drugs for attention-deficit/hyperactivity disorder. Pediatrics 122:451–453PubMedCrossRefGoogle Scholar
  19. 19.
    Schelleman H, Bilker WB, Strom BL, Kimmel SE, Newcomb C, Guevara JP, Daniel GW, Cziraky MJ, Hennessy S (2011) Cardiovascular events and death in children exposed and unexposed to ADHD agents. Pediatrics 127:1102–1110PubMedCrossRefGoogle Scholar
  20. 20.
    Shillingford AJ, Glanzman MM, Ittenbach RF, Clancy RR, Gaynor JW, Wernovsky G (2008) Inattention, hyperactivity, and school performance in a population of school-age children with complex congenital heart disease. Pediatrics 121:e759–e767PubMedCrossRefGoogle Scholar
  21. 21.
    U.S. Food and Drug Administation (2007) FDA directs ADHD drug manufacturers to notify patients about cardiovascular adverse events and psychiatric adverse events. http://www.fda.gov/bbs/topics/news/2007/new01568.html. Accessed Sep 2011
  22. 22.
    U.S. Food and Drug Administration (2005) Detailed view: safety labeling changes approved by FDA Center for Drug Evaluation and Research (CDER). http://www.fda.gov/medwatch/safety/2005/aug05.htm. Accessed Sep 2011
  23. 23.
    Vetter VL, Elia J, Erickson C, Berger S, Blum N, Uzark K, Webb CL (2008) Cardiovascular monitoring of children and adolescents with heart disease receiving medications for attention deficit/hyperactivity disorder (corrected): a scientific statement from the American heart association council on cardiovascular disease in the young congenital cardiac defects committee and the council on cardiovascular nursing. Circulation 117:2407–2423PubMedCrossRefGoogle Scholar
  24. 24.
    Warren AE, Hamilton RM, Bélanger SA, Gray C, Gow RM, Sanatani S, Côté JM, Lougheed J, LeBlanc J, Martin S, Miles B, Mitchell C, Gorman DA, Weiss M, Schachar R (2009) Cardiac risk assessment before the use of stimulant medications in children and youth: a joint position statement by the Canadian paediatric society, the Canadian cardiovascular society, and the Canadian academy of child and adolescent psychiatry. Can J Cardiol 25:625–630PubMedCrossRefGoogle Scholar
  25. 25.
    Wigal SB, Chae S, Patel A, Steinberg-Epstein R (2010) Advances in the treatment of attention-deficit/hyperactivity disorder: a guide for pediatric neurologists. Semin Pediatr Neurol 17:230–236PubMedCrossRefGoogle Scholar
  26. 26.
    Wilens TE, Prince JB, Spencer TJ, Biederman J (2006) Stimulants and sudden death: what is a physician to do? Pediatrics 118:1215–1219PubMedCrossRefGoogle Scholar
  27. 27.
    Wolraich ML, Greenhill LL, Pelham W, Swanson J, Wilens T, Palumbo D, Atkins M, McBurnett K, Bukstein O, August G (2001) Randomized, controlled trial of OROS methylphenidate once a day in children with attention-deficit/hyperactivity disorder. Pediatrics 108:883–892PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  • Anjan S. Batra
    • 1
    Email author
  • Mark E. Alexander
    • 2
  • Michael J. Silka
    • 3
  1. 1.Division of Pediatric CardiologyChildren’s Hospital of Orange County, University of California at IrvineOrangeUSA
  2. 2.Arrhythmia Service, Children’s Hospital BostonHarvard Medical SchoolBostonUSA
  3. 3.Division of Cardiology, Children’s Hospital Los AngelesUniversity of Southern CaliforniaLos AngelesUSA

Personalised recommendations